X4 Pharmaceuticals is focused on improving the lives of people with rare hematology diseases by developing innovative therapies
X4 Pharmaceuticals is focused on improving the lives of people with rare hematology diseases by developing innovative therapies. Their lead product, mavorixafor, is an orally available CXCR4 antagonist used for chronic neutropenic disorders.